News

CSI, ViperWire Advance Peripheral Guide Wire with Flex Tip, Stealth, Diamondback

Cardiovascular Systems Inc. announced that it has received U.S. Food and Drug Administration (FDA) clearance for its new ViperWire Advance Peripheral Guide Wire with Flex Tip for their peripheral...

ORBIT II, Diamondback 360, CSI, SCAI 2015, atherectomy

Cardiovascular Systems Inc. (CSI) featured two-year data from its ORBIT II study of the company’s Diamondback 360 coronary orbital atherectomy system (OAS) in a late-breaking presentation at...

CSI, Diamondback 360, atherectomy, PAD, Stealth 360

Cardiovascular Systems Inc. announced that it has received U.S. Food and Drug Administration (FDA) clearance for the 4 French, 1.25 Solid Diamondback 360 Peripheral Orbital Atherectomy System...

Aspire, Control Medical, thrombectomy, atherectomy devices, cath lab

George Adams, M.D., an interventional cardiologist with North Carolina Heart and Vascular, successfully treated a patient having an acute myocardial infarction (AMI) with the Aspire Mechanical...

Boston Scientific, Jetstream, CBSET, atherectomy, PAD

CBSET, a not-for-profit preclinical research institute, announced that its scientists have defined the optimal tissue debulking protocol for treating in-stent restenosis (ISR) with ...

peripheral arterial disease, Atherectomy devices, ISET

Ensuring that patients with peripheral arterial disease (PAD) get tested and treated with minimally invasive endovascular therapy saves legs and lives suggests a study in which amputation rates...

Covidien releases 12-month results of the DEFINITIVE AR study, the first randomized study designed to identify the clinical benefits of plaque removal using directional atherectomy ...

Cardiovascular Systems Inc. received the CE Mark for its Stealth 360º Orbital Atherectomy System (OAS). Stealth 360º is a percutaneous OAS that is indicated to treat patients who suffer from...

Food and Drug Administration gave 510(k) clearance for the HawkOne directional atherectomy system. The latest addition to Covidien’s directional atherectomy portfolio, the HawkOne system...

Cardiovascular Systems Inc. announced that the first seven patients in Japan have been enrolled in its Coronary Orbital Atherectomy System Trial (COAST) study. Taking place in the United States...

The first large prospective study to examine the effectiveness of laser atherectomy in the treatment of femoropopliteal in-stent restenosis (ISR) found that the procedure combined with...

Covidien TurboHawk Clinical Study Directional Atherectomy Effective PAD Therapy

Directional atherectomy is safe and effective as a frontline therapy for the treatment of peripheral arterial disease (PAD), according to a landmark Covidien study published online in the ...

Directional atherectomy is safe and effective as a frontline therapy for the treatment of peripheral arterial disease (PAD), according to a landmark Covidien study published online today in the...

Cardiovascular Systems is recalling certain lots of the Diamondback 360 Peripheral Orbital Atherectomy System, because they may contain defective saline sheaths that could fracture during use. If...

July 18, 2014 — Avinger announced that John Pigott, M.D., of Jobst Vascular Institute, Toledo, Ohio, enrolled the first patient in the VISION trial, a global investigational device exemption (IDE...

Cardiovascular Systems Inc. (CSI) announced that the first patient has been enrolled in its Coronary Orbital Atherectomy System Trial (COAST) trial.

June 9, 2014 — After one year, patients treated with orbital atherectomy, a procedure to sand away calcium in the coronary arteries prior to stenting, were less likely to require a repeat...

May 16, 2014 — In a move to expand significantly its portfolio of solutions for peripheral interventions, Boston Scientific Corp. has entered into a definitive agreement to acquire the...

Late-Breaking Trials SCAI May 2014

The Society for Cardiovascular Angiography and Interventions (SCAI) announced the late-breaking clinic al trial data presentations for it its upcoming 2014 Scientific Sessions, May 28-31, in Las...

Treatment options for high-risk heart patients with severely calcified coronary artery disease (CAD) have been limited for more than 20 years. Now, Robert Wood Johnson University Hospital (RWJUH)...